Clinical Study Of 131 Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib

Objective:To evaluate the efficacy and safety of sunitinib through following up 131 patients treated with sunitinib for metastatic renal cell carcinoma(mRCC).Methods:The 131 patients were enrolled from July 2008 to March 2016. The median age of them(103 male and 28 female) with metastatic renal cell carcinoma was 53 years(range from 24 to 73 years).All patients received radical nephrectomy before,126 cases had a diagnosis of clear-cell renal cell carcinoma(RCC),4 cases of papillary RCC, 1 case of chromophobe RCC. All patients were treated with sunitinib at a dosage of 50 mg daily for 4 weeks followed by a rest period of 2 weeks before the next new cycle. Then evaluate the efficacy and safety of sunitinib in the treatment of mRCC.Results:1 patient achieved complete response(CR) and 16 of them achieved partial response(PR).87 patients had stabilize disease(SD) while 27 of them had progressive disease. The objective response rate(ORR) was 13.0%. The disease control rate(DCR) was 79.4%. The median progression free survival(PFS) was 13.5months. During the therapy, the adverse effects included 94 cases of hand-foot syndrome,48 cases of hypertension,48 cases of thrombocytopenia,53 cases of anemia.Conclusion:Sunitinib is efficient in the treatment for mRCC. Most of adverse events can be tolerated, manageable and cured. It is helpful that finding personalized treatment programs when expanded samples studies are expected to confirm the efficacy and safety of sunitinib.